Whalesbook
Sanofi India's board has recommended a final dividend of ₹48 per equity share for the financial year ending December 31, 2025. The company also announced the appointment of Mr. Siraj Azmat Chaudhry as an Additional and Independent Director for a five-year term. These proposals will be presented for shareholder approval at the 70th Annual General Meeting (AGM) on April 29, 2026.
The recommended dividend follows a fiscal year in which Sanofi India reported a net profit of ₹3,267 million (approximately ₹326.7 crore). This move signifies the company's intent to reward its shareholders.
Mr. Chaudhry's five-year term as an Independent Director begins on April 1, 2026. He brings extensive leadership experience from various sectors, which is expected to add valuable perspectives to the board's strategic discussions and governance.
Part of the global healthcare group Sanofi S.A., Sanofi India has been a fixture in the Indian pharmaceutical market since 1956. The company offers a diverse portfolio spanning diabetes, cardiovascular health, consumer healthcare, and vaccines. It has a consistent history of distributing dividends, a practice generally favored by investors.
While the recent announcement focuses on positive corporate actions, it's noted that Sanofi India's growth has been below average compared to some industry peers in the past year. Shareholders will be awaiting formal approval of the dividend and Mr. Chaudhry's appointment at the upcoming AGM. Future performance and the impact of new leadership on strategic direction will be key areas to monitor. The company operates within a competitive market alongside major pharmaceutical firms like Sun Pharma, Cipla, and Dr. Reddy's.